J. Barbey

发表

Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation.

D. Echt, E. Cato, D. R. Coxe, 1989, Circulation.

Adenosine A1‐receptor occupancy predicts A1‐receptor antagonist effects of N‐0861

R. Benton, S. Yasuda, R. Woosley, 1998, Clinical pharmacology and therapeutics.

The electrocardiographic effects of cetirizine in normal subjects

R. Woosley, K. Thakker, J. Barbey, 1994, Clinical pharmacology and therapeutics.

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation

D. Abernethy, N. Ford, J. Barbey, 2001, Clinical pharmacology and therapeutics.

Antiarrhythmic activity, electrocardiogra phic effects andpharmacokinetics oftheencainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl

K. Thompson, J. Barbey, 1988 .

Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride: An ongoing independent case review

R. Lazzara, D. Zipes, J. Barbey, 2000 .

Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride

R. Lazzara, D. Zipes, J. Barbey, 2002, Journal of cardiovascular pharmacology and therapeutics.

Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

J. Pezzullo, D. Abernethy, D. Wesche, 2001, British journal of clinical pharmacology.

Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade.

K. Murray, D. Roden, C. Reilly, 1990, The Journal of clinical investigation.

The Impact of Posture on Cardiac Repolarization: More Than Heart Rate?

K. B. Hafner, J. Barbey, Ming‐yi Hu, 2006, Journal of cardiovascular electrophysiology.

A Simple In Vivo Model to Evaluate the Effects of Antiarrhythmic Agents

J. Barbey, A. Solomon, D. Syn, 1992, Pacing and clinical electrophysiology : PACE.

Factors influencing QT prolongation in patients hospitalized with severe anorexia nervosa.

C. Long, P. Mehler, M. Krantz, 2012, General hospital psychiatry.

Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.

S. Soignet, J. Barbey, S. Soignet, 2001, Annals of internal medicine.

Cardiac toxicity of arsenic trioxide.

J. Barbey, 2001, Blood.

Sodium Channel Block and Action Potential Prolongation

D. Echt, E. Cato, D. R. Coxe, 2005 .

Concentration/response relations for the multiple antiarrhythmic actions of sotalol.

T. Wang, C. Funck-Brentano, R. Woosley, 1990, The American journal of cardiology.

Drugs for the Prevention and Control of Syncope

J. Barbey, 2000 .

Vasodepressor syncope. Diagnosis and management.

J. Barbey, 1997, Cardiology clinics.

Drug-induced torsade de pointes: the perspectives of industry

J. Barbey, 2001 .

Vardenafil‐Associated QTc Changes: Not Merely a Normal Autonomic Process

J. Barbey, 2012, Clinical pharmacology and therapeutics.

Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.

D. Roden, K. Thompson, R. Woosley, 1988, Circulation.

Chlorpheniramine plasma concentration and histamine H1‐receptor occupancy

A. Wellstein, S. Yasuda, R. Woosley, 1995, Clinical pharmacology and therapeutics.

SSRI safety in overdose.

S. Roose, J. Barbey, 1998, The Journal of clinical psychiatry.

Effect of arsenic trioxide on QT interval in patients with advanced malignancies.

S. Soignet, J. Pezzullo, J. Barbey, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

d‐Sotalol reduces heart rate in vivo through a β‐adrenergic receptor–independent mechanism

A. Wellstein, C. Funck-Brentano, S. Yasuda, 1993, Clinical pharmacology and therapeutics.

Effect o f A rsenic T rioxide o n Q T I nterval i n P atients W ith Advanced M alignancies

S. Soignet, J. Pezzullo, J. Barbey, 2003 .

Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia

J. Saul, M. Schaffer, P. Hinderling, 2001, Clinical pharmacology and therapeutics.

Tocainide plus quinidine for treatment of ventricular arrhythmias.

D. Roden, K. Thompson, R. Woosley, 1988, The American journal of cardiology.

Alterations in Heart Rate Following Radiofrequency Ablation in the Treatment of Reentrant Supraventricular Arrhythmias: Relation to Alterations in Autonomic Tone

C. Tracy, J. Barbey, R. Verdino, 1997, Journal of Interventional Cardiac Electrophysiology.

Clinical pharmacokinetics of moricizine.

R. Woosley, S. Schwartz, L. Siddoway, 1990, The American journal of cardiology.

Man versus Machine: Comparison of Automated and Manual Methodologies for Measuring the QTc Interval: A Prospective Study

M. Krantz, J. Barbey, B. Beaty, 2016, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle‐aged subjects

R. Woosley, P. Hinderling, J. Barbey, 1999, Clinical pharmacology and therapeutics.

Mexiletine and tocainide: A comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing

K. Murray, D. Roden, H. Kopelman, 1989, Clinical pharmacology and therapeutics.